Fig. 4From: The benefits and risks of pembrolizumab in combination with chemotherapy as first-line therapy in small-cell lung cancer: a single-arm meta-analysis of noncomparative clinical studies and randomized control trialsForest plots of grade 3-4 adverse effects rate (A) and discontinuation treatment rate (B)Back to article page